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Abstract
We describe a consanguineous family in which two brothers were affected by
childhood onset spastic ataxia with optic atrophy and loss of motor and
language skills. Through a combination of homozygosity mapping and whole-
genome sequencing, we identified a homozygous copy number variant in GLS
as the cause. The duplication leads to complete knockout of GLS expression.
GLS encodes the brain- and kidney-specific enzyme glutaminase, which hydro-
lyzes glutamine for the production of glutamate, the most abundant central
nervous system neurotransmitter. This is the first report implicating GLS loss of
function in human disease.
Introduction
Autosomal recessive spastic ataxias are a diverse group
of neurodegenerative disorders caused by mutations in
a variety of genes including SACS,1 KIF1C,2 MARS2,3
and AFG3L2.4 These genes encode proteins with a
variety of cellular functions, from the ubiquitin–
proteasome system to axonal transport and protein
translation.
Symptoms usually develop in childhood and include
variable degrees of cerebellar ataxia and lower limb spas-
ticity, often accompanied by optic atrophy, dystonia, and
epilepsy. In this study, we describe a family affected by
autosomal recessive spastic ataxia with optic atrophy, in
whom whole-exome sequencing failed to make a diagno-
sis. By employing a combination of whole-genome
sequencing and homozygosity mapping, we detected a
homozygous duplication spanning exon 1 of the gene
GLS, leading to complete loss of GLS mRNA and protein
expression. This is the first time that the loss of function
GLS mutations have been implicated in human disease.
Materials and Methods
Next-generation sequencing
Whole-exome sequencing was performed with the Agilent
SureSelect All Exon kit (Agilent, California, USA) as pre-
viously described.5 Whole-genome sequencing was per-
formed by deCODE genetics. Genomic coordinates were
numbered according to the hg19 build of the human
genome reference.
Duplication-specific PCR and functional
studies
Duplication-specific PCR was carried out on gDNA
using the following primers; Forward: GTCTCGCT CTG
TCACACAGG, Reverse: TCACTGATAAGCCCTGCCAA.
For RT-PCR analysis, total RNA was extracted from
leukocytes, and reverse transcribed to cDNA using the
High Capacity cDNA Synthesis kit (Applied Biosystems).
A PCR was then performed with the following primers;
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Forward: CTGTCCAGCTCTCCTTCGG, Reverse: ACAGC
AAATCTTCCAAGCTAGG.
For Western blotting, total proteins were extracted
from cultured fibroblasts, resolved by SDS-PAGE and
transferred to PVDF membranes. For glutaminase, the
following knockout validated antibody was used: Anti-
Glutaminase antibody, Abcam ab156876, which recognizes
both the KGA and GAC isoforms, and for loading con-
trol, Anti-beta Actin antibody (Abcam ab8226) was used.
Results
Clinical findings
We identified a family in which two brothers were
affected by an aggressive form of spastic ataxia with optic
atrophy. The parents of the affected patients were cousins
and were from a geographically isolated region of Turkey.
The inheritance pattern was autosomal recessive, and the
Figure 1. MRI imaging of Patient 1 demonstrates mild cerebellar atrophy with preservation of the cerebral and brainstem volumes and normal
white matter signal.
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two patients included in this study were the only affected
members in the family. Initially, both boys developed
normally, with an uneventful pregnancy and delivery, and
reached motor and language milestones at appropriate
ages. At the age of 5 years, both boys had normal motor
coordination, and could run and play games. They
attended school and there were no concerns with their
cognitive or motor development. However, at the age of
7 years, both boys began to develop difficulty with coor-
dination and gait. By the age of 8, they began to develop
visual loss due to progressive optic atrophy. With time,
the syndrome progressed into a profound ataxia with
upper motor neuron signs and loss of language skills.
Visual impairment progressed to perception of light only
at 14 years.
At the age of 27 and 30, now both patients can
stand and walk only with assistance, and are otherwise
wheelchair dependent. There is optic atrophy and bilat-
eral gaze evoked nystagmus with some limitation of
upgaze. Tone is increased in the upper and lower limbs
with symmetrically brisk reflexes. There is significant
limb and truncal ataxia. Speech is profoundly dysarthric
and language skills are limited to the repetition of
single words, such as names. Sensory examination is
normal.
MRI imaging in both patients demonstrated mild cere-
bellar atrophy with preservation of the cerebral and brain-
stem volumes and normal white matter signal (Fig. 1).
Nerve conduction studies and muscle biopsy were nor-
mal, indicating that the syndrome is confined to the cen-
tral nervous system. An extensive series of tests for
childhood neurodegenerative diseases was negative includ-
ing metabolic testing for Batten’s Disease and Neuronal
Ceroid Lipofuscinosis.
GLS
A B
C
Figure 2. Family pedigree is shown (A), where filled boxes indicate affected patients. Homozygosity mapping identified three regions of
significant homozygosity on Chromosomes 2, 8, and 14 (B). Whole-genome sequencing identified an approximately 8 Kb region with significantly
increased read depth and split-paired reads spanning exon 1 of the gene GLS, indicating a duplication (C).
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Genetic results
Considering the pedigree and history of consanguinity,
we felt that this syndrome was likely to be due to a
homozygous mutation. To identify the causative muta-
tion, we first carried out whole-exome sequencing (WES)
on both affected family members. We employed a filtering
strategy to prioritize rare, homozygous variants shared
between both affected patients that were likely to affect
protein function. However, this strategy did not identify
any potentially disease-causing mutations. To exclude the
possibility that the causative gene lay within a region of
poor exome coverage, we then carried out whole-genome
sequencing (WGS) on Patient 1.
We prioritized rare homozygous variants with likely
deleterious effect not contained in our in house WGS
database. This also failed to identify any likely pathogenic
variants. To narrow the disease locus, we carried out gen-
ome wide genotyping on all available family members
using the Illumina CytoSNP12 array, and used Homozy-
gosityMapper6 to identify shared regions of homozygosity
in affected patients.
This identified 3 shared homozygous regions present in
both siblings (Fig. 2B). With the hypothesis that the dis-
ease-causing mutation could be a copy number variant or
structural rearrangement, we used the software program
LUMPY,7 to analyze the WGS data on Patient 1. We lim-
ited our analysis to CNVs found within the linked
homozygous regions that overlapped with the coding
region of a gene, and were therefore likely to have a func-
tional outcome. LUMPY identified only one such variant,
an 8 kb duplication spanning exon 1 of the gene GLS. A
large increase in read depth and split reads mapping to
the duplication breakpoint were visible in IGV (Fig. 2C).
The breakpoints of the duplication were predicted to lie
within AluSx SINE elements, which are approximately
90% homologous, implying the mechanism of duplication
as nonallelic homologous recombination. At an RNA
level, a duplication of exon 1 would lead to a premature
stop codon with likely nonsense mediated decay (NMD)
of the affected transcript.
To confirm the presence of the duplication and map
its breakpoint more precisely, duplication-specific PCR
was performed. In both children and parents,
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Figure 3. After duplication-specific PCR, a band is visible in the parents, and affected offspring, but not in controls (A). Reverse transcription PCR
showed absent or severely reduced GLS RNA compared to control or to the parents (B). Reduced glutaminase protein levels were confirmed by
Western blotting (C). GLS is highly expressed in brain from early development, and is widely expressed in cerebellum and cortex in data from the
BRAINEAC consortium (D).
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duplication-specific PCR revealed an aberrant band and
sequencing confirmed the breakpoint to have occurred
between a highly homologous region of Intron 1-2 (Chr
2: 191750021) and the 50 untranslated region (Chr2:
191742079) (Fig. 3A).
To characterize the effect of the duplication on RNA,
we extracted total RNA from peripheral blood leukocytes
and reverse transcribed it to cDNA. In the affected
patients, GLS cDNA was either not present or was
severely reduced. A control RT-PCR for GAPDH was used
to confirm the presence of intact cDNA in all samples
(Fig. 3B). We concluded that the homozygous duplication
leads to complete knockout of GLS expression in patient
tissue. This was confirmed by western blotting using a
glutaminase antibody on whole-cell lysates extracted from
fibroblast cell lines of the patients, their parents, and two
unrelated controls (Fig. 3C).
Discussion
GLS encodes the brain- and kidney-specific enzyme glu-
taminase, which hydrolyzes glutamine for the production
of glutamate. Since neurons cannot synthesize glutamate
de novo from glucose, they depend heavily on the recy-
cling of glutamine and glutamate between neurons and
astrocytes for neurotransmission.
This occurs when glutamate at the synapse is imported
into astrocytes and converted to glutamine. This glu-
tamine diffuses into the extracellular space and is take up
by neuron presynaptic terminals, where glutaminase con-
verts it to glutamate. The glutamate is then packaged into
synaptic vesicles for release.
In keeping with its essential role in the glutamate path-
way, GLS is widely expressed in all brain regions from
early development, with highest levels found in the cere-
bral cortex and cerebellum (Fig. 3D, from the BRAINEAC
database8). The gene is intolerant to loss of function
mutations in humans, with a pLi score9 of 1.
Interestingly, GLS -/- mice die shortly after birth.10
Cultured neurons from the mice show a reduction in
depolarization-evoked glutamate release and altered exci-
tatory postsynaptic potentials (EPSCs). In addition, it has
been shown that knockdown of GLS in human neural
progenitor cells (NPCs) leads to a significant reduction in
NPC survival and ability to differentiate into neurons.11
Taken together, these findings would predict that com-
plete loss of GLS expression would not be compatible
with human growth and development. However, we
clearly show that GLS is not absolutely required for early
human development, although complete absence of GLS
activity leads to a complex phenotype with aggressive,
childhood onset spastic ataxia, and optic atrophy. The
lack of significant brain atrophy on imaging, and the
prominent involvement of the optic nerves, for which
glutamate is the primary excitatory neurotransmitter, sup-
ports our findings that the syndrome described here is
primarily due to a functional failure of neurotransmis-
sion, rather than an alternative neurodegenerative process.
This report raises important questions about the mech-
anism of glutamate recycling and neurotransmission in
humans. We hypothesize that survival is due to a com-
pensatory mechanism, either through increased expression
of GLS2 isoforms in the CNS, or through an alternative
process to generate glutamate, such as from a-ketoglutarate
by the enzyme alanine transaminase. This report also adds
to the number of synaptic genes implicated in neurological
diseases, including in spastic ataxias, such as VAMP1.
In summary, through a combination of whole-genome
sequencing, homozygosity mapping and functional stud-
ies, we show that GLS knockout is compatible with
human life, and causes childhood onset spastic ataxia and
optic atrophy.
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